financetom
Business
financetom
/
Business
/
Ball, O-I Glass, Sylvamo Show Momentum, Catalysts, Value, BofA Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ball, O-I Glass, Sylvamo Show Momentum, Catalysts, Value, BofA Says
Nov 17, 2025 9:32 AM

12:05 PM EST, 11/17/2025 (MT Newswires) -- Ball (BALL), O-I Glass ( OI ) , and Sylvamo ( SLVM ) have momentum and catalysts that make them attractive, BofA Securities said Monday in a research note updating its packaging, paper, and forest products coverage for year-end.

Analysts said Ball should grow in line with or above the industry over the next two years, supported by contracts and new capacity in the second half of 2026, with North and Central America growth expected to reach about 1.9% in 2026 and 2.0% in 2027.

O-I Glass ( OI ) faces some risk from soft beer and alcohol demand, but its Fit to Win initiatives are driving earnings momentum, BofA said. Sylvamo ( SLVM ) is positioned to benefit from improving supply-demand conditions in North American paper and higher pulp pricing.

Commodity wood products such as lumber and plywood show limited near-term upside, and BofA said there has not yet been a recovery in pricing.

The firm said it is below consensus on earnings for PotlatchDeltic ( PCH ) and Weyerhaeuser (WY), noting that lumber and construction-related markets are likely to remain stagnant during winter.

BofA upgraded Ball and O-I Glass ( OI ) to buy from neutral, with price objectives of $61 and $17, respectively. Sylvamo ( SLVM ) was upgraded to buy from underperform with a $59 price objective.

PotlatchDeltic ( PCH ) was downgraded to underperform from buy, with a $46 price objective, while Weyerhaeuser was downgraded to neutral from buy, with a $26 price objective.

Price: 47.65, Change: +0.05, Percent Change: +0.11

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Apple Faces Brighter Days Despite Weak iPhone Sales in China, Wedbush Says
Apple Faces Brighter Days Despite Weak iPhone Sales in China, Wedbush Says
Mar 5, 2024
12:04 PM EST, 03/05/2024 (MT Newswires) -- Apple ( AAPL ) may be navigating a stormy period in the near term amid weak iPhone sales in China, but the company is likely to see brighter days ahead, Wedbush said in a note Tuesday. Apple's ( AAPL ) decision to abandon its electric vehicle project to focus solely on artificial intelligence...
Planet 13 Holdings Prices Public Offering -- Shares Down Near 23%
Planet 13 Holdings Prices Public Offering -- Shares Down Near 23%
Mar 5, 2024
12:00 PM EST, 03/05/2024 (MT Newswires) -- Planet 13 Holdings Inc. ( PLNH ) has priced its previously announced underwritten public offering. The company will issue and sell 18.75 million units at US$0.60 each for total gross proceeds of US$11.3 million. The underwriters have also been granted a 15% over-allotment option, which, if fully exercised, will yield total gross proceeds...
Lennar Poised for Fiscal Q1 Orders Beat Amid Volume Strategy, Wedbush Says
Lennar Poised for Fiscal Q1 Orders Beat Amid Volume Strategy, Wedbush Says
Mar 5, 2024
12:03 PM EST, 03/05/2024 (MT Newswires) -- Lennar's ( LEN ) volume strategy is expected to help the company report better-than-projected fiscal Q1 orders, Wedbush Securities said Tuesday. The homebuilder is scheduled to report fiscal Q1 financial results on March 13. Wedbush projects earnings at $2.16 per share, with revenue seen jumping nearly 17% year-over-year to about $7.49 billion. The...
Vir Biotechnology Completes Enrollment in Phase 2 Chronic Hepatitis Delta Trial Ahead of Schedule
Vir Biotechnology Completes Enrollment in Phase 2 Chronic Hepatitis Delta Trial Ahead of Schedule
Mar 5, 2024
12:05 PM EST, 03/05/2024 (MT Newswires) -- Vir Biotechnology ( VIR ) said Tuesday it completed enrollment of its current groups in a phase 2 clinical trial of tobevibart and elebsiran to treat chronic hepatitis delta virus one month earlier than projected. The company said this includes more than 60 participants in two additional groups, with one evaluating tobevibart given...
Copyright 2023-2026 - www.financetom.com All Rights Reserved